Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells 2,186 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insider Jeffrey Farrow sold 2,186 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $146,462.00. Following the completion of the sale, the insider owned 43,316 shares in the company, valued at $2,902,172. This trade represents a 4.80% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock traded down $1.49 during midday trading on Thursday, hitting $66.75. 461,600 shares of the company’s stock were exchanged, compared to its average volume of 672,393. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The stock has a 50-day moving average price of $69.36 and a two-hundred day moving average price of $70.18. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market cap of $2.84 billion, a P/E ratio of -41.20 and a beta of 0.55.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%. On average, equities research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Tarsus Pharmaceuticals News Summary

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

Institutional Trading of Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Deep Track Capital LP grew its position in Tarsus Pharmaceuticals by 71.4% during the third quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock valued at $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Tarsus Pharmaceuticals by 34.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,930,325 shares of the company’s stock worth $158,062,000 after acquiring an additional 491,326 shares during the last quarter. Norges Bank bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth approximately $19,095,000. M&T Bank Corp boosted its stake in shares of Tarsus Pharmaceuticals by 11,730.0% in the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock valued at $35,791,000 after purchasing an additional 433,424 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter valued at $13,834,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Analyst Ratings Changes

Several brokerages have issued reports on TARS. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. The Goldman Sachs Group restated a “neutral” rating and set a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Zacks Research downgraded shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 25th. Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $91.83.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.